Zhi Tong Cai Jing·2026-01-27 08:53Core Viewpoint - The company, CanSino Biologics (06185), anticipates significant revenue growth and a turnaround in profitability by the end of 2025, driven by innovative product offerings and effective cost management [1] Financial Projections - The company expects to achieve operating revenue between RMB 1.04 billion and RMB 1.08 billion for the year ending December 31, 2025, representing an increase of RMB 194 million to RMB 234 million compared to the previous year, which translates to a year-on-year growth of 22.88% to 27.61% [1] - The projected net profit attributable to the owners of the parent company is expected to be between RMB 24.5 million and RMB 29 million, indicating a return to profitability compared to the previous year [1] - The expected net loss attributable to the owners of the parent company, after excluding non-recurring gains and losses, is projected to be between RMB 91 million and RMB 96 million [1] Strategic Focus - The company continues to implement a development strategy centered on innovation and commercialization, with the first four-valent meningococcal vaccine, Manhaixin, showing sustained revenue growth [1] - The company has made significant progress in cost reduction and efficiency improvement, effectively managing various expenses, which has led to an increase in gross margin [1] - Overall profitability has significantly improved, achieving a positive net profit attributable to the owners of the parent company during the reporting period [1] Research and Funding - The rapid advancement of the company's R&D projects and international collaborations has resulted in increased government grants and international funding support, contributing to substantial non-recurring income during the reporting period [1]